Drugs / RG7893
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02856152 | Jun → Nov 2016 | — | Genentech, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG7893 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707353 ↗ |
| Known as | GDC-0276 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02856152 ↗ |
| Action | Inhibit | “Sodium channel protein type IX alpha subunit blocker” CHEMBL3707353 ↗ |
| Route | Oral | “Three 90 milligram \[mg\] capsules of GDC-0276 administered orally.” NCT02856152 ↗ |
| Target | SCN9A | “Sodium channel protein type IX alpha subunit blocker” CHEMBL3707353 ↗ |